Novartis Oncology is conducting clinical research for the treatment of neuroendocrine tumors and neuroendocrine carcinoma (carcinoid tumors). These trials are called RADIANT-2 and RADIANT-3. This research is designed to evaluate an investigational drug called RAD001 (everolimus) in patients with carcinoid tumors or pancreatic neuroendocrine tumors. To learn more about this research and to see if you may qualify to participate, click on the link below.